US FDA clarifies how drug firms can import products prior to approval
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is proposing to create a formal program for how the agency deals with requests to import unapproved finished dosage form drug products by manufacturers that want to prepare the product for market launch, based on anticipated approval of a pending marketing application1,2.